Findings

What do systematic reviews say?

35 questions · 35 findings · 15 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 12 · 34.3%GRADE not reported 1 · 2.9%Very low 10 · 28.6%Low 6 · 17.1%Moderate 6 · 17.1%High 0 · 0%

Flutamide 250 mg b.i.d. vs placebo

Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cilostazol vs placebo

Quality of life (change in points, SF‐36, WIQ) · intermittent claudication

1 finding from 1 review

Cilostazol for intermittent claudication 2021 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1163 participants
Low

Intervention not reported

Change in quality of life Measures: QWB, HAQUAMS, MSIS‐29, SF‐36, LMSQOLS, · People with multiple sclerosis

1 finding from 1 review

Telerehabilitation for persons with multiple sclerosis 2015 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 392 participants
Low

Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone

Health status and quality of life · people with advanced gastric cancer

1 finding from 1 review

Molecular‐targeted first‐line therapy for advanced gastric cancer 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 53 participants
Very low

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

Quality of life ‐ (EuroQol) EQ‐5D‐3L Index Score (total score): absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1061 participants
Moderate

Self‐management interventions vs usual care

Quality of life Change scores/post intervention SF‐12 or ‐36: physical or mental functioning EuroQol; SAQoL; SSQoL · people with stroke

Self management programmes showed no clear difference in quality of life Change scores/post intervention SF‐12 or ‐36:… compared with usual care (low certainty).

1 finding from 1 review

Self management programmes for quality of life in people with stroke 2016 · Cochrane Headline outcomes only
SMD 0.2 [0, 0.41]
6 studies · 469 participants
Low

Topical antibiotics with steroids vs topical steroid

Change from baseline in quality of life IDQoL ranges from 0 to 30 with higher values indicating more impaired quality of life · people with eczema

1 finding from 1 review

Interventions to reduce Staphylococcus aureus in the management of eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 42 participants
Moderate

Oral antibiotics vs placebo

Change from baseline in quality of life IDQoL ranges from 0 to 30 with higher values indicating more impaired quality of life. · people with atopic dermatitis

1 finding from 1 review

Interventions to reduce Staphylococcus aureus in the management of eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 45 participants
Moderate

Intervention not reported

Self‐perceived QoL (change from baseline) measured using Peds QL 4.0 Generic Core Scales, scoring 0‐100 points, higher score indicates better quality of life) · children with chronic constipation

1 finding from 1 review

Transcutaneous electrical stimulation (TES) for treatment of constipation in children 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 33 participants
Very low

Intervention not reported

Parent‐perceived QoL (change from baseline) measured using PedsQL 4.0 Generic Core Scales, scoring 0‐100 points, higher score indicates better quality of life) · children with chronic constipation

1 finding from 1 review

Transcutaneous electrical stimulation (TES) for treatment of constipation in children 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 33 participants
Very low

Patisiran vs placebo

QoL · people with TTR‐FAP

1 finding from 1 review

Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 225 participants
Low

Inotersen vs placebo

QoL · people with TTR‐FAP

1 finding from 1 review

Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 172 participants
Low

Tafamidis vs placebo

QoL · people with early‐stage TTR‐FAP

1 finding from 1 review

Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 125 participants
Very low

Mechanically assisted walking training with body weight support vs no walking training

Quality of life Measured by: PedsQOL‐CP score (range from 0 to 100; higher scores = better quality of life) Timing of outcome assessment: change scores from baseline to 12 weeks · children with cerebral palsy classified within GMFCS Levels I to V and between 3 and 18 years of age

1 finding from 1 review

Mechanically assisted walking training for walking, participation, and quality of life in children with cerebral palsy 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 26 participants
Low

Anti‐VEGF vs sham

QoL · macular oedema secondary to branch retinal vein occlusion

1 finding from 1 review

Anti‐vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 281 participants
Moderate